Search

Your search keyword '"Avonex (Medication) -- Product introduction"' showing total 13 results
Start Over Descriptor "Avonex (Medication) -- Product introduction"
13 results on '"Avonex (Medication) -- Product introduction"'

1. Biogen Idec Inc. at Jefferies Global Healthcare Conference - Final

Subjects
Biogen Idec Inc. -- Conferences, meetings and seminars -- Product introduction -- Officials and employees, Biological products industry -- Conferences, meetings and seminars -- Product introduction -- Officials and employees, Health care industry -- Conferences, meetings and seminars -- Product introduction -- Officials and employees, Health care industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction, Tecfidera (Medication) -- Product introduction
Abstract

Presentation THOMAS WEI, ANALYST, JEFFERIES & CO.: We're going to get the next session started here. Welcome to the Jefferies Healthcare Conference. My name is Thomas Wei. I'm one of [...]

Published
2013

2. Biogen Idec Inc. at Deutsche Bank dbAccess Health Care Conference - Final

Subjects
Deutsche Bank AG (Frankfurt, Germany) -- Conferences, meetings and seminars -- Product introduction, Biogen Idec Inc. -- Conferences, meetings and seminars -- Product introduction, Biological products industry -- Conferences, meetings and seminars -- Product introduction, Banks (Finance) -- Conferences, meetings and seminars -- Product introduction, Banking industry -- Conferences, meetings and seminars -- Product introduction, Health care industry -- Conferences, meetings and seminars -- Product introduction, Health care industry, Banking industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction, Tecfidera (Medication) -- Product introduction, Copaxone (Medication) -- Product introduction
Abstract

Presentation ROBYN KARNAUSKAS, ANALYST, DEUTSCHE BANK: Good afternoon. My name is Robyn Karnauskas. I am one of the Deutsche Bank biotechnology analysts. Next we have Biogen presenting the CEO, George [...]

Published
2013

3. Biogen Idec Inc. at Cowen Health Care Conference - Final

Subjects
Biogen Idec Inc. -- Conferences, meetings and seminars -- Product introduction, Biological products industry -- Conferences, meetings and seminars -- Product introduction, Health care industry -- Conferences, meetings and seminars -- Product introduction, Health care industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction
Abstract

Presentation ERIC SCHMIDT, ANALYST, COWEN AND COMPANY: Okay. Good afternoon, everyone, and welcome back to Cowen and Company's 32nd (sic - see slides) Annual Healthcare Conference. It's my pleasure to [...]

Published
2013

4. Biogen Idec Inc. at Citi Global Healthcare Conference - Final

Subjects
Citigroup Inc. -- Conferences, meetings and seminars -- Product introduction, Biogen Idec Inc. -- Conferences, meetings and seminars -- Product introduction, Biological products industry -- Conferences, meetings and seminars -- Product introduction, Financial services industry -- Conferences, meetings and seminars -- Product introduction, Health care industry -- Conferences, meetings and seminars -- Product introduction, Health care industry, Financial services industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction
Abstract

Presentation YARON WERBER, ANALYST, CITIGROUP: Okay, well, good afternoon, everybody and thanks once again for joining us here at the Citi Global Healthcare Conference. It is a great pleasure to [...]

Published
2013

5. Biogen Idec Inc. at JPMorgan Global Healthcare Conference Presentation - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars -- Product introduction, Biogen Idec Inc. -- Conferences, meetings and seminars -- Product introduction, Biological products industry -- Conferences, meetings and seminars -- Product introduction, Interferon beta -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars -- Product introduction, Health care industry -- Conferences, meetings and seminars -- Product introduction, Health care industry, Banking industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction
Abstract

Presentation GEOFF MEACHAM, ANALYST, J.P. MORGAN: Good afternoon and welcome to day one of the J. P. Morgan Healthcare Conference. My name is Geoff Meacham. I am the senior biotech [...]

Published
2013

6. Event Brief of Novartis AG , Gilenya, one year after first launch: Conference Call - Final

Subjects
The Goldman Sachs Group Inc. -- Product introduction, Novartis AG -- Product introduction, Societe Generale S.A. -- Product introduction, Brain damage -- Risk factors -- Care and treatment, Interferon -- Product introduction, Medical research, Medicine, Experimental, Multiple sclerosis -- Risk factors -- Care and treatment, Banking industry -- Product introduction, Investment banks -- Product introduction, Biological response modifiers, Cardiac patients -- Care and treatment, Pharmaceutical industry -- Product introduction, Banking industry, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction, Gilenya (Medication) -- Product introduction
Abstract

PARTICIPANTS . Pierre-Michel Bringer, Novartis AG, IR . Gordon Francis, Novartis AG, Head - Clinical Scientific Unit . Barry Singer, MS Center for Innovations in Care, Director . Marietta Miemietz, [...]

Published
2011

7. Novartis AG , Gilenya, one year after first launch: Conference Call - Final

Subjects
Novartis AG -- Product introduction, Brain damage -- Risk factors -- Care and treatment, Interferon -- Product introduction, Medical research, Medicine, Experimental, Multiple sclerosis -- Risk factors -- Care and treatment, Biological response modifiers, Cardiac patients -- Care and treatment, Pharmaceutical industry -- Product introduction, Business, Tysabri (Medication) -- Product introduction, Avonex (Medication) -- Product introduction, Gilenya (Medication) -- Product introduction
Abstract

Presentation OPERATOR: Good morning or good afternoon, depending on where you're attending from. I'm Stephanie, the Chorus Call operator for this conference. Welcome to the conference call and webcast regarding [...]

Published
2011

8. Avonex

Subjects
Biogen Idec Inc. -- Product introduction, Avonex (Medication) -- Product introduction, Product introduction, Drugs -- Product introduction, Biotechnology industries -- Product introduction, Biotechnology industry -- Product introduction
Abstract

Avonex, from Biogen Idec, Cambridge, Mass., (617) 6792000, may now be stored in its prefilled formulation for up to seven days at room temperature--up to 77°F or 25°C). Avonex is [...]

Published
2006

9. Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Subjects
Interferon -- Product introduction -- Forecasts and trends, Multiple sclerosis -- Forecasts and trends, Biological response modifiers -- Forecasts and trends, Market trend/market analysis, General interest, News, opinion and commentary, Avonex (Medication) -- Product introduction
Abstract

May 15, 2013 (M2 PRESSWIRE via COMTEX) -- Research and Markets (http://www.researchandmarkets.com/research/zk5xkd/avonex_multiple) has announced the addition of the 'Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022' report to [...]

Published
2013

10. Research and Markets: Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Subjects
Bayer AG -- Forecasts and trends -- Product introduction, Interferon -- Product introduction, Multiple sclerosis, Biological response modifiers, Pharmaceutical industry -- Forecasts and trends -- Product introduction, Market trend/market analysis, Business, Business, international, Avonex (Medication) -- Product introduction
Abstract

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/bxgv8m/avonex_multiple) has announced the addition of the 'Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022' report to their offering. GlobalData has released its [...]

Published
2013

11. Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Subjects
Bayer AG -- Forecasts and trends -- Product introduction, Multiple sclerosis, Pharmaceutical industry -- Forecasts and trends -- Product introduction, Market trend/market analysis, Business, Business, international, Avonex (Medication) -- Product introduction
Abstract

M2 PRESSWIRE-May 15, 2013-: Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022(C)1994-2013 M2 COMMUNICATIONS RDATE:15052013 Dublin - Research and Markets (http://www.researchandmarkets.com/research/zk5xkd/avonex_multiple) has announced the addition of the 'Avonex [...]

Published
2013

12. New drug aims to win over MS sufferers

Author

Johannes, Laura

Subjects
Biogen Inc. -- Product introduction -- 00322550, Chiron Corp. -- Market share -- 00320322, Multiple sclerosis -- Drug therapy, Biotechnology industry -- Product introduction, Business, Business, general, Avonex (Medication) -- Product introduction, Betaseron (Medication) -- Market share
Published
1996

13. Avonex Multiple Sclerosis - Forecast and Market Analysis to 2022

Subjects
Avonex (Medication) -- Product introduction, Product introduction, Forecasts and trends, Market trend/market analysis, Multiple sclerosis -- Forecasts and trends
Abstract

By a News Reporter-Staff News Editor at Biotech Week -- Research and Markets (http://www.researchandmarkets.com/research/bxgv8m/avonex_multiple) has announced the addition of the 'Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022' [...]

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results